GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roivant Sciences Ltd (NAS:ROIV) » Definitions » PB Ratio

Roivant Sciences (Roivant Sciences) PB Ratio : 1.45 (As of May. 26, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Roivant Sciences PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-26), Roivant Sciences's share price is $10.98. Roivant Sciences's Book Value per Share for the quarter that ended in Dec. 2023 was $7.57. Hence, Roivant Sciences's PB Ratio of today is 1.45.

Good Sign:

Roivant Sciences Ltd stock PB Ratio (=1.45) is close to 3-year low of 1.31

The historical rank and industry rank for Roivant Sciences's PB Ratio or its related term are showing as below:

ROIV' s PB Ratio Range Over the Past 10 Years
Min: 1.31   Med: 2.89   Max: 10.61
Current: 1.45

During the past 3 years, Roivant Sciences's highest PB Ratio was 10.61. The lowest was 1.31. And the median was 2.89.

ROIV's PB Ratio is ranked better than
71.19% of 1312 companies
in the Biotechnology industry
Industry Median: 2.5 vs ROIV: 1.45

During the past 12 months, Roivant Sciences's average Book Value Per Share Growth Rate was 475.40% per year.

Back to Basics: PB Ratio


Roivant Sciences PB Ratio Historical Data

The historical data trend for Roivant Sciences's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roivant Sciences PB Ratio Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23
PB Ratio
- 2.07 4.85

Roivant Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.08 4.85 8.49 9.86 1.48

Competitive Comparison of Roivant Sciences's PB Ratio

For the Biotechnology subindustry, Roivant Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Roivant Sciences's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Roivant Sciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Roivant Sciences's PB Ratio falls into.



Roivant Sciences PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Roivant Sciences's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=10.98/7.566
=1.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Roivant Sciences  (NAS:ROIV) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Roivant Sciences PB Ratio Related Terms

Thank you for viewing the detailed overview of Roivant Sciences's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Roivant Sciences (Roivant Sciences) Business Description

Traded in Other Exchanges
Address
50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a biopharmaceutical company dedicated to improving the delivery of healthcare to patients.
Executives
Eric Venker officer: President & COO C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 6TH FLOOR, NEW YORK NY 10018
Keith S Manchester director C/O ROIVANT SCIENCES LTD., 11-12 ST. JAMES'S SQUARE SUITE 1, 3RD FL, LONDON X0 SW1Y 4L
Daniel Allen Gold director 6720 VIA AUSTI PARKWAY, SUITE 450, LAS VEGAS NV 89119
Qvt Financial Lp 10 percent owner, other: Director by Deputization 888 SEVENTH AVENUE, 43RD FLOOR, NEW YORK NY 10106
Svf Investments (uk) Ltd 10 percent owner 69 GROSVENOR STREET, LONDON X0 W1K3JP
Rakhi Kumar officer: Chief Accounting Officer C/O NEUROPACE INC, 455 N BERNARDO AVENUE, MOUNTAIN VIEW CA 94043
Viking Global Investors Lp 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Viking Global Performance Llc 10 percent owner 55 RAILROAD AVENUE, 3RD FLOOR, GREENWICH CT 06830
Sumitomo Chemical Co., Ltd. 10 percent owner 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020
Viking Global Opportunities Parent Gp Llc 10 percent owner 600 WASHINGTON BLVD., FLOOR 11, STAMFORD CT 06901
Softbank Vision Fund L.p. 10 percent owner AZTEC GROUP HOUSE, 11-15 SEATON PLACE, ST HELIER Y9 JE4 0QH
Meghan Fitzgerald director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Richard Pulik officer: CFO SUITE 1, 3RD FLOOR, 11-12 ST. JAMES'S SQUARE, LONDON X0 SW1Y 4LB
Vivek Ramaswamy director C/O ONCORE BIOPHARMA, INC., 3805 OLD EASTON ROAD, DOYLESTOWN PA 18902
Dexcel Pharma Technologies Ltd. 10 percent owner 1 DEXCEL STREET, OR AKIVA L3 3060000